Consolidated and Combined Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		8 Months Ended	9 Months Ended
	Jan. 29, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2022
Operating expenses:
Research and development	$ 662	$ 36,744	$ 25,850	$ 54,126	$ 127,248
General and administrative	121	12,284	12,464	29,900	41,432
Change in fair value of contingent value rights	0	0	0	11,312	1,980
Acquired in-process research and development	0	0	0	220,454	0
Loss from operations	(783)	(49,028)	(38,314)	(315,792)	(170,660)
Interest (expense) income, net	(9)	(1,845)	65	100	(4,869)
Amortization of debt discount	(37)	0	0	0	0
Other income (expense), net	0	(3,143)	(1,906)	(4,605)	2,412
Loss before income taxes	(829)	(54,016)	(40,155)	(320,297)	(173,117)
Income taxes	0	(141)	0	0	(83)
Net loss	(829)	(53,875)	(40,155)	(320,297)	(173,034)
Other comprehensive loss:
Foreign currency translation adjustment	107	(553)	(487)	2,828	(2,383)
Total comprehensive loss	$ (722)	$ (54,428)	$ (40,642)	$ (317,469)	$ (175,417)
Net loss per ordinary share - basic (in dollars per share)		$ (0.57)	$ (0.45)	$ (4.60)	$ (1.86)
Net loss per ordinary share - diluted (in dollars per share)		$ (0.57)	$ (0.45)	$ (4.60)	$ (1.86)
Weighted average ordinary shares outstanding - basic (in shares)		94,327,914	89,899,454	69,597,648	92,994,990
Weighted average ordinary shares outstanding - diluted (in shares)		94,327,914	89,899,454	69,597,648	92,994,990